Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Drugs Made In America Acquisition II Corp. ( (DMII) ) is now available.
On March 11, 2026, Drugs Made In America Acquisition II Corp. issued a $150,000 unsecured convertible bridge note to Alpha Multi Family Office as part of a planned $1.4 million convertible notes financing under a previously disclosed letter of intent, and on March 24, 2026, the parties entered into a definitive investment and sponsor transition agreement to advance that financing. On March 30, 2026, the company issued a second, $300,000 interim convertible note maturing in nine months with no interest and an investor option to convert into shares of the post-merger entity at a 35% discount to market, with proceeds earmarked for accounting, audit, and other expenses related to its initial business combination, underscoring both its funding needs and the investor’s opportunity for discounted equity participation.
The issuance of the $300,000 interim convertible note on March 30, 2026 strengthens the company’s funding base for completing its initial business combination and related professional costs, while also creating a direct financial obligation on its balance sheet. The 35% discount conversion feature into shares of the combined entity aligns the investor’s upside with the success of the future business combination and signals confidence in the company’s ability to close a transaction under the newly signed definitive investment and sponsor transition agreement.
More about Drugs Made In America Acquisition II Corp.
Drugs Made In America Acquisition II Corp. is a special purpose acquisition company focused on executing an initial business combination, using targeted financings to cover transaction-related costs such as accounting and audit expenses. The company aims to complete its first business combination and may offer investors equity-linked upside through convertible note structures tied to the combined entity’s share price.
Average Trading Volume: 113,112
Current Market Cap: $655.1M
See more data about DMII stock on TipRanks’ Stock Analysis page.